Literature DB >> 11371254

Deep vein thrombosis and its prevention in critically ill adults.

J Attia1, J G Ray, D J Cook, J Douketis, J S Ginsberg, W H Geerts.   

Abstract

BACKGROUND: Our objective was to systematically review the incidence of deep vein thrombosis (DVT) and the efficacy of thromboprophylaxis in critically ill adults, including patients admitted to intensive care units and following trauma, neurosurgery, or spinal cord injury.
METHODS: Two authors independently searched MEDLINE, EMBASE, abstract databases, and the Cochrane database. Data were extracted independently in triplicate.
RESULTS: Ten percent to 30% of medical and surgical intensive care unit patients develop DVT within the first week of intensive care unit admission. The use of subcutaneous low-dose heparin reduced the rate by 50% compared with no prophylaxis. Approximately 60% of trauma patients developed DVT within the first 2 weeks of admission. Use of unfractionated heparin appears to decrease the incidence of DVT by only 20%, whereas low-molecular-weight heparin decreases the incidence by a further 30%. The estimated prevalence of DVT in neurosurgical patients not given prophylaxis is 22% to 35%. Mechanical prophylaxis is efficacious, with a pooled odds ratio in 5 randomized trials of 0.28. Use of low-molecular-weight heparin has been investigated as an adjunct to mechanical prophylaxis with a pooled odds ratio of 0.59 compared with graduated compression stockings alone. The incidence of DVT without prophylaxis in acute spinal cord injury patients is likely in excess of 50% to 80%. Studies of prophylaxis in these patients are too sparse to come to any definitive conclusion.
CONCLUSIONS: Critically ill patients commonly develop DVT, with rates that vary from 22% to almost 80%, depending on patient characteristics. Methods of prophylaxis proven in one group do not necessarily generalize to other critically ill patient groups. More potent prophylactic regimens other than unfractionated or low-molecular-weight heparins alone may be needed with higher-risk groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371254     DOI: 10.1001/archinte.161.10.1268

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  71 in total

1.  [Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology].

Authors:  W Gogarten; K Hoffmann; H Van Aken
Journal:  Unfallchirurg       Date:  2010-11       Impact factor: 1.000

Review 2.  Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.

Authors:  G Eymin; A K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 3.  Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography.

Authors:  Eduardo Gonzalez; Fredric M Pieracci; Ernest E Moore; Jeffry L Kashuk
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

4.  Linking joint commission inpatient core measures and national patient safety goals with evidence.

Authors:  Andrew L Masica; Kathleen M Richter; Paul Convery; Ziad Haydar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-04

5.  Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.

Authors:  Timothy R Smith; Rishi R Lall; Randall B Graham; Jamal Mcclendon; Rohan R Lall; Allan D Nanney; Joseph G Adel; Anaadriana Zakarija; James P Chandler
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

6.  Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices?

Authors:  K M Sauro; A Soo; A Kramer; P Couillard; J Kromm; D Zygun; D J Niven; S M Bagshaw; H T Stelfox
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

7.  Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Authors:  Scott Worley; Christine Short; Jeff Pike; David Anderson; Jo-Anne Douglas; Kara Thompson
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

8.  A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients.

Authors:  Henry T Stelfox; Rebecca Brundin-Mather; Andrea Soo; Jeanna Parsons Leigh; Daniel J Niven; Kirsten M Fiest; Christopher James Doig; Danny J Zuege; Barry Kushner; Fiona Clement; Sharon E Straus; Deborah J Cook; Sean M Bagshaw; Khara M Sauro
Journal:  Intensive Care Med       Date:  2019-02-01       Impact factor: 17.440

9.  Surveillance or no surveillance ultrasonography for deep vein thrombosis and outcomes of critically ill patients: a pre-planned sub-study of the PREVENT trial.

Authors:  Yaseen M Arabi; Karen E A Burns; Sami J Alsolamy; Mohammed S Alshahrani; Fahad M Al-Hameed; Zia Arshad; Mohammed Almaani; Hassan Hawa; Yasser Mandourah; Ghaleb A Almekhlafi; Abdulsalam Al Aithan; Imran Khalid; Jalal Rifai; Gulam Rasool; Sheryl Ann I Abdukahil; Jesna Jose; Lara Y Afesh; Abdulaziz Al-Dawood
Journal:  Intensive Care Med       Date:  2020-02-24       Impact factor: 17.440

Review 10.  [Venous thromboembolism prophylaxis].

Authors:  B Dohmen; W Gogarten; R Kuhlen; R Rossaint
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.